英國實施臨床試驗法規重大改革
UK Implements Major Clinical Trial Regulatory Overhaul
2026年4月28日，英國對其臨床試驗法規進行了歷史性的全面改革，標誌著二十年來最重大的變革。
On April 28, 2026, the United Kingdom launched a historic overhaul of its clinical trial regulations, marking the most significant change in two decades.
基於扭轉註冊率下滑並促進生命科學發展的需求，這些改革旨在精簡行政程序的同時，維持安全性作為首要考量。
Driven by the need to reverse declining enrollment rates and boost life sciences, these reforms aim to cut red tape while keeping safety at the forefront.
透過揚棄「一體適用」的方法，英國採用了一套風險比例制。
By moving away from a one-size-fits-all approach, the UK has adopted a risk-proportionate system.
這意味著低風險研究現面臨較寬鬆的審查，而高風險研究則接受必要的密集監管。
This means low-risk studies now face lighter scrutiny, while high-risk research receives the necessary intensive oversight.
此項變革的核心在於正式將英國藥品與保健產品管理局(MHRA)和健康研究管理局(HRA)的聯合審查編入法規，這已成功縮短了試驗啟動時間。
A centerpiece of this change is the formal codification of combined reviews by the MHRA and HRA, which has already successfully reduced trial setup times.
此外，新規則強制要求透明化，要求研究人員公開註冊試驗並與參與者分享淺顯易懂的研究結果。
Furthermore, the new rules mandate transparency, requiring researchers to register trials publicly and share plain-language results with participants.
隨著英國在脫歐後自行規劃路徑，它選擇採取主權監管框架，而非依賴歐盟系統。
As the UK charts its own path post-Brexit, it is intentionally opting for a sovereign regulatory framework rather than relying on EU systems.
這項策略將英國定位為更靈活、更具競爭力的醫療創新中心，最終透過更有效率、數位化的研究環境，協助病患更快獲得救命療法。
This strategy positions the nation as a more agile, competitive hub for medical innovation, ultimately helping patients gain faster access to life-saving treatments through a more efficient, digitally-enabled research landscape.
